Cardiology update 2017: The first quarter

In the first quarter of 2017, proprotein convertase subtilisin/kexin type 9's role got defined further with a number of trials such as FOURIER, ORION-1, and SPIRE 1 and 2. TAVI proves safe in intermediate-risk patients in the Surgical Replacement and Transcatheter Aortic Valve Implantation stud...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the practice of cardiovascular sciences 2017-01, Vol.3 (1), p.18-21
Main Author: Sridharan Umapathy
Format: Article
Language:English
Subjects:
Cardiology
newer anticoagulants
proprotein convertase subtilisin/kexin type 9
TAVI
update 2017
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In the first quarter of 2017, proprotein convertase subtilisin/kexin type 9's role got defined further with a number of trials such as FOURIER, ORION-1, and SPIRE 1 and 2. TAVI proves safe in intermediate-risk patients in the Surgical Replacement and Transcatheter Aortic Valve Implantation study. Newer anticoagulants extended their role to valvular heart disease. Bioabsorbable stent showed problems (ABSORB 2 and 3). New guidelines have been released for syncope and transcatheter aortic valve replacement implantation. Clinical outcome studies involving instantaneous wave-free ratio (IFR) showed IFR to be noninferior to fractional flow reserve. Optimal medical therapy proves noninferior to percutaneous coronary intervention in single vessel chronic total occlusion.
ISSN:2395-5414
2454-2830
DOI:10.4103/jpcs.jpcs_16_17